이승환 (Seung Hwan Lee)

SeungHwan Lee
SeungHwan Lee

 

♦ Educational Background
Seoul National University College of Medicine, Seoul, Korea : M.D. (2007)
Seoul National University Graduate School, Seoul, Korea : M.S. in Clinical Pharmacology (2010)
Seoul National University Graduate School, Seoul, Korea : PhD in Clinical Pharmacology (2012)

 

♦ Professional Background
2007. 3 ~ 2008. 2 Internship, SNU Hospital, Seoul, Korea
2008. 3 ~ 2012. 2 Resident, Department of Clinical Pharmacology and Therapeutics, SNU Hospital, Seoul, Korea
2008. 3 ~ 2012. 2 Research and Teaching Assistant, Department of Pharmacology, College of Medicine, Seoul National University, Seoul, Korea
2012. 4 ~ 2015. 4 Captain (Medical researcher), Armed Forces Medical Research Institute, Daejeon, Korea
2013. 3 ~ 2014. 8 Lecturer, Armed Forces Medical, Korea Armed Forces Nursing Academy, Daejeon, Korea
2015. 5 ~ Present Clinical Assistant Professor, Clinical Trials Center & Department of Clinical Pharmacology and Therapeutics, SNU Hospital, Seoul, Korea

 

♦ GCP Certification
Last investigator advanced education for clinical trials professionals (6hr): 30 Jun 2016

 

♦ Membership
Korean Medical Association
Korean Society for Clinical Pharmacology and Therapeutics
Korean Society of Pharmacology
Population Approach Group in Korea
Korean Society for Mass Spectrometry
American Society for Clinical Pharmacology and Therapeutics
Population Approach Group in Europe
Society for Clinical Data Management

 

♦ Publications

  • Lee S, Lim KS, Kim J, Kim BH, Cho JY, Yoon SH, et al. Pharmacokinetics of Irsogladin Maleate in Healthy Korean Volunteers. J Korean Soc Clin Pharmacol Ther. 2009;17:35-43.
  • Lee S, Chung YJ, Kim BH, Shim JH, Yoon SH, Shin SG, et al. Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. Clin Ther. 2009;31:3000-8.
  • Kim SE, Shin KH, Kim TE,Lee S, Kim BH, Kim MJ, et al. Pharmacokinetics and safety of LB80380, LB80920 and LB80331 after oral Administration of LB80380 in Healthy Male Volunteers. J Korean Soc Clin Pharmacol Ther. 2010;18:34-42.
  • Cha YJ, Kim JW, Jeon H, Shin KH, Lee S, Jang IJ, et al. Pharmacokinetics andTolerability of Naftopidil after a Single Oral Administration in Healthy KoreanVolunteers. J Korean Soc Clin Pharmacol Ther. 2010;18:127-36.
  • Cha RH, Lee CS, Lim YH, Kim H,Lee SH, Yu KS, et al. Clinical usefulness of serum cystatin C and the pertinent estimation of glomerular filtration rate based on cystatin C. Nephrology (Carlton). 2010;15:768-76.
  • Lee S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. Clin Ther. 2010;32:2496-501.
  • Lee S, Park WB, Shin KH, Ahn DH, Yoon SH, Cho JY, et al. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults. Vaccine. 2011;29:7638-43.
  • Jeon H,Lee S, Kim TE, Yoon SH, Shin SG, Jang IJ, et al. Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers. Int J
    Clin Pharmacol Ther. 2011;49:688-95.
  • Yoon S,Lee S, Oh DS, Lim KS, Shin SG, Jang IJ, et al. Evaluation of Pharmacokinetics and Tolerability of Eplerenone after Multiple Oral Doses of 100mg in Healthy Korean Volunteers. J Korean Soc Clin Pharmacol Ther. 2011;19:84-90.
  • Kim KH,Lee S, Lee S, Yun NR, Kim NJ, Yu KS, et al. Voriconazole-associated severe hyponatremia. Med Mycol. 2012;50:103-5.
  • Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple
    doses in healthy volunteers. J Clin Pharmacol. 2012;52:195-203.
  • Lee S, Gu N, Kim BH, Lim KS, Shin SG, Jang IJ, et al. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose,parallel-group study. Clin Ther. 2012;34:1160-9.
  • Lee JW, Kang HJ,Lee SH, Yu KS, Kim NH, Yuk YJ, et al. Highly variablepharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant. 2012;18:944-50.
  • Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080-7.
  • Lee S, Chung JY, Hong KS, Yang SH, Byun SY, Lim HS, et al. Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets. J Clin Pharm Ther.
    2012;37:553-7.
  • Shin D, Shin KH,Lee S, Lim KS, Cho JY, Jang IJ, et al. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. Int J Clin Pharmacol Ther 2012;50:722-8.
  • Lee S, Kim BH, Lim K, Stalker D, Wisemandle W, Shin SG, et al. Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects. J Cli Pharm Ther. 2012;37:698-703.
  • Kim S, Lee S, Lim KS, Lim HS, Shin SG, Jang IJ, et al. Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers. J Korean Soc Clin Pharmacol Ther. 2012;20:125-34.
  • Jeon H, Jang IJ, Lee S, Ohashi K, Kotegawa T, Ieiri I, et al. Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol. 2013;75:172-9.
  • Kim B, Moon JY, Choi MH, Yang HH, Lee S, Lim KS, et al. Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alter endogenous urinary steroid markers. Journal of proteome research. 2013;12:1359-68.
  • Shin D,Lee S, Lim KS, Park JS, Shin SG, Jang IJ, et al. Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women. Contraception. 2013;87:750-5.
  • Kim SE, Kim BH, Lee S, Sohn JA, Kim HS, Cho JY, et al. Population pharmacokinetics of theophylline in premature Korean infants. Therapeutic drug monitoring. 2013;35:33-44.
  • Oh J, Lee S, Lim KS, Chung JY, Shin SG, Jang IJ, et al. A Randomized, Placebo Controlled, Double Blind, Parallel Group, Multiple Dosing, Dose Escalation Clinical Study to Evaluate Pharmacokinetics/Pharmacodynamics and Tolerability of Zofenopril in Healthy Korean Subjects. J Korean Soc Clin Pharmacol Ther. 2013;21:52-62.
  • Yoon S, Lee H, Kim TE,Lee S, Chee DH, Cho JY, et al. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and itsimmediate-release reference formulation in healthy volunteers. Drug design, development and therapy. 2014;8:123-8.
  • Oh J, Shin D, Lim KS,Lee S, Jung KH, Chu K, et al. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Clinical pharmacology and therapeutics. 2014;95:608-16.
  • Shin D, Cho YM,Lee S, Lim KS, Kim JA, Ahn JY, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clinical drug investigation. 2014;34:383-93.
  • Kim TE, Lee H, Lim KS, Lee S, Yoon SH, Park KM, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014;78:556-64.
  • Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim NH, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2015;21:190-5.
  • Oh YJ, Cha RH, Lee SH, Yu KS, Kim SE, Kim H, et al. Validation of the Korean coefficient for the modification of diet in renal disease study equation. Korean J Intern Med. 2016;31:344-56.
  • Rhee SJ, Lee S, Yoon SH, Cho JY, Jang I J, Yu KS. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. Drug design, development and therapy. 2016;10:1411-8.
  • Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, et al. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug design, development and therapy.2016;10:25 25-34.
  • Choi Y, Lee S, Cho SM, Kang WH, Nam KY, Jang IJ, et al. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: arandomized, open-label, single-dose, two-period, two-sequence crossover study. Drug design, development and therapy. 2016;10:3021-8.
  • Lee J, Ji SC, Kim B, Yi S, Shin KH, Cho JY, et al. Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches. Clin Transl Sci. 2016.
  • Kim S, Chung H,Lee S, Cho SH, Cho HJ, Kim SH, et al. Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28-0126 in healthy male subjects. Br J Clin Pharmacol. 2016.
  • Lee SW, Yoon S, Yu KS, Lee S. Therapeutic drug monitoring of vancomycin in a patient with Duchenne muscular dystrophy (DMD): A case report. Transl Clin Pharmacol. 2016;24:124-6.
  • Yoon J, Moon SJ, Lee KO, Yoon SH, Jang IJ, Yu KS, Lee S. Comparison of R(+)-α-lipoic acid exposure after R(+)-α-lipoic acid 200 mg and 300 mg and thioctic acid 600 mg in healthy Korean male subjects. Transl Clin Pharmacol. 2016;24:137-42.
  • Oh J, Kim AH, Lee S, Cho H, Kim YS, Bahng MY, et al. Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). Diabetes Obes Metab. 2017;19:294-8.
  • Kim Y, Yim S, Kim BH,Lee S. Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2017;55 (2017):102-8.
  • Lee H, Yim SV, Kim BH, Lee S. Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects. Int  Clin Pharmacol Ther. 2017;55 (2017):95-101.
  • Lee HA, Lee S, Yim SV, Kim BH. Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects. Int J Clin Pharmacol Ther. 2017;55(2017):171-6.
  • Yoon S, Lee S, Yu KS, Yim SV, Kim BH. Pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects. Int J Cli Pharmacol Ther. 2017;55 (2017):194-200.

 

Back